247 related articles for article (PubMed ID: 1484319)
1. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
2. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
3. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
Esposito V; Baldi A; De Luca A; Claudio PP; Signoriello G; Bolognese A; Centonze P; Giordano GG; Caputi M; Baldi F; Giordano A
Anticancer Res; 1997; 17(1B):733-6. PubMed ID: 9066611
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
Ramael M; Lemmens G; Eerdekens C; Buysse C; Deblier I; Jacobs W; van Marck E
J Pathol; 1992 Dec; 168(4):371-5. PubMed ID: 1484318
[TBL] [Abstract][Full Text] [Related]
5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
6. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
7. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
Cagle PT; Brown RW; Lebovitz RM
Hum Pathol; 1994 May; 25(5):443-8. PubMed ID: 8200637
[TBL] [Abstract][Full Text] [Related]
8. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
9. [Thoracoscopic anatomy, significance of pathologic findings in thoracoscopic open lung biopsy, and pleural mesothelioma].
Kawai T; Watanabe M; Takagi K
Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Dec; 32 Suppl():142-7. PubMed ID: 7602822
[TBL] [Abstract][Full Text] [Related]
10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
[TBL] [Abstract][Full Text] [Related]
13. Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens.
Marchevsky AM; Gil J; Caccamo D
Arch Pathol Lab Med; 1985 Dec; 109(12):1102-5. PubMed ID: 3840984
[TBL] [Abstract][Full Text] [Related]
14. p53 expression is common in malignant mesothelioma.
Kafiri G; Thomas DM; Shepherd NA; Krausz T; Lane DP; Hall PA
Histopathology; 1992 Oct; 21(4):331-4. PubMed ID: 1398535
[TBL] [Abstract][Full Text] [Related]
15. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
16. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
Roberts F; McCall AE; Burnett RA
J Clin Pathol; 2001 Oct; 54(10):766-70. PubMed ID: 11577123
[TBL] [Abstract][Full Text] [Related]
17. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
18. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
19. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
